These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 21341682)
1. Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. Laborde E; Macsata RW; Meng F; Peterson BT; Robinson L; Schow SR; Simon RJ; Xu H; Baba K; Inagaki H; Ishiwata Y; Jomori T; Matsumoto Y; Miyachi A; Nakamura T; Okamoto M; Handel TM; Bernard CC J Med Chem; 2011 Mar; 54(6):1667-81. PubMed ID: 21341682 [TBL] [Abstract][Full Text] [Related]
2. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. Brodmerkel CM; Huber R; Covington M; Diamond S; Hall L; Collins R; Leffet L; Gallagher K; Feldman P; Collier P; Stow M; Gu X; Baribaud F; Shin N; Thomas B; Burn T; Hollis G; Yeleswaram S; Solomon K; Friedman S; Wang A; Xue CB; Newton RC; Scherle P; Vaddi K J Immunol; 2005 Oct; 175(8):5370-8. PubMed ID: 16210643 [TBL] [Abstract][Full Text] [Related]
3. Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis. Lebre MC; Vergunst CE; Choi IY; Aarrass S; Oliveira AS; Wyant T; Horuk R; Reedquist KA; Tak PP PLoS One; 2011; 6(7):e21772. PubMed ID: 21747955 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2. Buntinx M; Hermans B; Goossens J; Moechars D; Gilissen RA; Doyon J; Boeckx S; Coesemans E; Van Lommen G; Van Wauwe JP J Pharmacol Exp Ther; 2008 Oct; 327(1):1-9. PubMed ID: 18599682 [TBL] [Abstract][Full Text] [Related]
5. Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists. Yang L; Zhou C; Guo L; Morriello G; Butora G; Pasternak A; Parsons WH; Mills SG; MacCoss M; Vicario PP; Zweerink H; Ayala JM; Goyal S; Hanlon WA; Cascieri MA; Springer MS Bioorg Med Chem Lett; 2006 Jul; 16(14):3735-9. PubMed ID: 16698264 [TBL] [Abstract][Full Text] [Related]
6. Alpha-aminothiazole-gamma-aminobutanoic amides as potent, small molecule CCR2 receptor antagonists. Zhou C; Guo L; Parsons WH; Mills SG; MacCoss M; Vicario PP; Zweerink H; Cascieri MA; Springer MS; Yang L Bioorg Med Chem Lett; 2007 Jan; 17(2):309-14. PubMed ID: 17092717 [TBL] [Abstract][Full Text] [Related]
7. Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists. Xia M; Hou C; DeMong DE; Pollack SR; Pan M; Brackley JA; Jain N; Gerchak C; Singer M; Malaviya R; Matheis M; Olini G; Cavender D; Wachter M J Med Chem; 2007 Nov; 50(23):5561-3. PubMed ID: 17929797 [TBL] [Abstract][Full Text] [Related]
8. Preventive CCL2/CCR2 Axis Blockade Suppresses Osteoclast Activity in a Mouse Model of Rheumatoid Arthritis by Reducing Homing of CCR2 Flegar D; Filipović M; Šućur A; Markotić A; Lukač N; Šisl D; Ikić Matijašević M; Jajić Z; Kelava T; Katavić V; Kovačić N; Grčević D Front Immunol; 2021; 12():767231. PubMed ID: 34925336 [TBL] [Abstract][Full Text] [Related]
9. CCR2 Expression in Neutrophils Plays a Critical Role in Their Migration Into the Joints in Rheumatoid Arthritis. Talbot J; Bianchini FJ; Nascimento DC; Oliveira RD; Souto FO; Pinto LG; Peres RS; Silva JR; Almeida SC; Louzada-Junior P; Cunha TM; Cunha FQ; Alves-Filho JC Arthritis Rheumatol; 2015 Jul; 67(7):1751-9. PubMed ID: 25779331 [TBL] [Abstract][Full Text] [Related]
10. Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. De Lucca GV; Kim UT; Vargo BJ; Duncia JV; Santella JB; Gardner DS; Zheng C; Liauw A; Wang Z; Emmett G; Wacker DA; Welch PK; Covington M; Stowell NC; Wadman EA; Das AM; Davies P; Yeleswaram S; Graden DM; Solomon KA; Newton RC; Trainor GL; Decicco CP; Ko SS J Med Chem; 2005 Mar; 48(6):2194-211. PubMed ID: 15771462 [TBL] [Abstract][Full Text] [Related]
11. Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Gouwy M; Struyf S; Noppen S; Schutyser E; Springael JY; Parmentier M; Proost P; Van Damme J Mol Pharmacol; 2008 Aug; 74(2):485-95. PubMed ID: 18469140 [TBL] [Abstract][Full Text] [Related]
12. CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis. Raghu H; Lepus CM; Wang Q; Wong HH; Lingampalli N; Oliviero F; Punzi L; Giori NJ; Goodman SB; Chu CR; Sokolove JB; Robinson WH Ann Rheum Dis; 2017 May; 76(5):914-922. PubMed ID: 27965260 [TBL] [Abstract][Full Text] [Related]
13. The obesity and inflammatory marker haptoglobin attracts monocytes via interaction with chemokine (C-C motif) receptor 2 (CCR2). Maffei M; Funicello M; Vottari T; Gamucci O; Costa M; Lisi S; Viegi A; Ciampi O; Bardi G; Vitti P; Pinchera A; Santini F BMC Biol; 2009 Dec; 7():87. PubMed ID: 20017911 [TBL] [Abstract][Full Text] [Related]
14. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. Mirzadegan T; Diehl F; Ebi B; Bhakta S; Polsky I; McCarley D; Mulkins M; Weatherhead GS; Lapierre JM; Dankwardt J; Morgans D; Wilhelm R; Jarnagin K J Biol Chem; 2000 Aug; 275(33):25562-71. PubMed ID: 10770925 [TBL] [Abstract][Full Text] [Related]
16. The molecular structure and role of CCL2 (MCP-1) and C-C chemokine receptor CCR2 in skeletal biology and diseases. Zhu S; Liu M; Bennett S; Wang Z; Pfleger KDG; Xu J J Cell Physiol; 2021 Oct; 236(10):7211-7222. PubMed ID: 33782965 [TBL] [Abstract][Full Text] [Related]